Literature DB >> 9368085

Nosocomial enterococcal blood stream infections in the SCOPE Program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. SCOPE Hospital Study Group.

R N Jones1, S A Marshall, M A Pfaller, W W Wilke, R J Hollis, M E Erwin, M B Edmond, R P Wenzel.   

Abstract

Characteristics of nosocomial enterococcal blood stream infection (NEBSI) isolates obtained from patients at 41 U.S. hospitals participating in the SCOPE Program were studied. Isolates from 480 episodes of NEBSI were characterized according to species and antimicrobial susceptibility profile. Selected isolates were also identified to species and vancomycin resistance genotype using polymerase chain reaction based methods. Polymerase chain reaction genotyping and ribotyping were used as genetic markers for molecular epidemiologic typing. Enterococci were the third most common cause of nosocomial blood stream infection in this study, accounting for 11.7% of all isolates reported. Enterococcus faecalis was the most common species (59.6%), followed by E. faecium (19.4%). Species identification errors involving E. faecium, E. durans, E. avium, and E. raffinosus were observed. Vancomycin resistance was observed in 36.4% of all participating medical centers and varied from 11.1% of medical centers in the Northwest to 60.9% of medical centers in the Southwest. Vancomycin-resistant enterococci accounted for 20.6% of NEBSI in the Northeast, 11.4% in the Southeast, 11.1% in the Southwest, and 9.5% in the Northwest regions. VanA genotypes predominated in the Northeast and Southwest, whereas vanA and vanB genotypes were equally prevalent in the Northwest and Southeast. Molecular typing studies identified strains that were unique to individual hospitals as well as strains that were prevalent in several different hospitals. NEBSI with vancomycin-resistant enterococci continues to escalate among hospitalized patients in all geographic areas of the USA.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9368085     DOI: 10.1016/s0732-8893(97)00115-6

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  27 in total

1.  Role of global surveillance in combating bacterial resistance.

Authors:  A Marchese; G C Schito
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Classification and identification of enterococci: a comparative phenotypic, genotypic, and vibrational spectroscopic study.

Authors:  C Kirschner; K Maquelin; P Pina; N A Ngo Thi; L P Choo-Smith; G D Sockalingum; C Sandt; D Ami; F Orsini; S M Doglia; P Allouch; M Mainfait; G J Puppels; D Naumann
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

3.  Comparison of an automated ribotyping system to restriction endonuclease analysis and pulsed-field gel electrophoresis for differentiating vancomycin-resistant Enterococcus faecium isolates.

Authors:  Connie S Price; Holly Huynh; Suzanne Paule; Richard J Hollis; Gary A Noskin; Michael A Pfaller; Lance R Peterson
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

4.  Development of a thermally regulated broad-spectrum promoter system for use in pathogenic gram-positive species.

Authors:  David A Schofield; Caroline Westwater; Brian D Hoel; Phillip A Werner; James S Norris; Michael G Schmidt
Journal:  Appl Environ Microbiol       Date:  2003-06       Impact factor: 4.792

5.  Widespread Emergence of Multidrug Resistant Pseudomonas aeruginosa Isolated from CSF Samples.

Authors:  S Nagaveni; H Rajeshwari; Ajay Kumar Oli; S A Patil; R Kelmani Chandrakanth
Journal:  Indian J Microbiol       Date:  2011-01-26       Impact factor: 2.461

6.  Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America.

Authors:  Leonard A Mermel; Michael Allon; Emilio Bouza; Donald E Craven; Patricia Flynn; Naomi P O'Grady; Issam I Raad; Bart J A Rijnders; Robert J Sherertz; David K Warren
Journal:  Clin Infect Dis       Date:  2009-07-01       Impact factor: 9.079

7.  Multicenter study evaluating the role of enterococci in secondary bacterial peritonitis.

Authors:  Emilia Cercenado; Luis Torroba; Rafael Cantón; Luis Martínez-Martínez; Fernando Chaves; Jose Angel García-Rodríguez; Carmen Lopez-Garcia; Lorenzo Aguilar; César García-Rey; Nuria García-Escribano; Emilio Bouza
Journal:  J Clin Microbiol       Date:  2009-11-25       Impact factor: 5.948

8.  In vivo activities of evernimicin (SCH 27899) against vancomycin-susceptible and vancomycin-resistant enterococci in experimental endocarditis.

Authors:  M Souli; C Thauvin-Eliopoulos; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

9.  Use of molecular and reference susceptibility testing methods in a multicenter evaluation of MicroScan dried overnight gram-positive MIC panels for detection of vancomycin and high-level aminoglycoside resistances in enterococci.

Authors:  Y S Chen; S A Marshall; P L Winokur; S L Coffman; W W Wilke; P R Murray; C A Spiegel; M A Pfaller; G V Doern; R N Jones
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

10.  Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model.

Authors:  R E Lewis; B C Lund; M E Klepser; E J Ernst; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.